APOE and metabolic dysfunction-associated steatohepatitis: Studies show that APOE4 patients are more resistant to chronic HCV infection, have a slow progression of liver fibrosis, and are less likely to have alcoholic cirrhosis, non-alcoholic steatohepatitis (NASH) hepatocellular carcinoma (HCC), or virus hepatitis B (HBV) (34–36).